At Fluxion, we’re passionate about delivering cell-based and cell-free solutions that facilitate the transformation of research discoveries into new ways to diagnose and treat patients. By characterizing molecular and cellular mechanisms of disease, Fluxion’s platforms help bridge the translational medicine gap, enabling rapid advances in disease research, drug discovery, and the development of diagnostic tests.
Comprehensive studies of ligand-gated receptors depend on reliable, accurate and repetitive responses of said receptors to the co-application of agonists. If a liquid exchange is not precise and complete, receptor desensitization will ultimately act as the limiting factor in an assay.
What is discussed: Data will be presented showing how the new flow control technology implemented in IonFlux Mercury can enhance existing ligand-gated assays (Nicotinic and GABA receptors) limiting receptor desensitization and increasing reproducibility of currents.